Gilead Sciences, Inc.
NEWS
In order to continue to provide patients with access to the potential treatment, Gilead said it is in the process of transitioning from individual compassionate use requests to expanded access programs.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
The recommended dose of the drug for this age group is based on weight and liver function.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chairman and chief executive officer.
JOBS
IN THE PRESS